Cellectis S.A.
NASDAQ:CLLSBiotechnology
-$0.02 today
- Market cap
- $103.75M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
Volume 0.01M
Average 0.04M
CLLS Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Cellectis S.A.NASDAQ: CLLS
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables declines year over year
Q1 FY2026 accounts payables of $3.87M (cash outflow) fell 38.4% year over year, ahead of the -181.1% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 4.5% of revenue in FY2025, down 0.5 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -38.4% holds above the trailing-twelve-month pace of -181.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (3.27M) USD
- Year-over-year change
- -259.4%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (3.27M) | -259.4% |
| FY2024 | 2024-12-31 | 2.05M | +132.5% |
| FY2023 | 2023-12-31 | (6.31M) | -294.2% |
| FY2022 | 2022-12-31 | 3.25M | +1734.5% |
| FY2021 | 2021-12-31 | 177K | — |
Accounts Payables vs competitors
How CLLS compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -181.1% is the 6th highest of 8, against a peer median of +128.8%.
- Accounts payables amounts to 2.0% of revenue for CLLS, versus a peer median of 66.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.22M USD | +128.8% | — | 8.0% | |
| LTM Mar 2026 | $5.87M USD | +736.9% | +375.3% | — | |
| LTM Mar 2026 | $5.6M USD | — | — | 608.1% | |
| LTM Mar 2026 | $4.34M USD | -72.9% | +66.1% | — | |
| LTM Mar 2026 | $2.56M USD | -290.8% | — | 66.7% | |
| LTM Mar 2026 | $1.98M USD | +327.2% | -39.7% | — | |
| LTM Mar 2026 | $1.34M USD | -181.1% | — | 2.0% | |
| LTM Mar 2026 | $456.35K USD | +226.0% | — | 91.3% | |
| LTM Dec 2025 | $337K USD | — | +15.3% | — | |
| LTM Dec 2025 | CHF 327.34K CHF | — | — | 9.2% | |
| LTM Mar 2026 | $204.79K USD | -411.0% | -70.8% | — | |
| Peer median (excluding CLLS) | — | +128.8% | +15.3% | 66.7% | |
Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (96.75M) | (98.69M) | (116.84M) | (36.7M) | (67.8M) |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.84M | 20.12M |
| Deferred Income Tax | 0 | 87K | 371K | 0 | 0 |
| Stock-Based Compensation | 11.49M | 6.04M | 5.23M | 0 | 0 |
| Change in Working Capital | (12.3M) | (5.72M) | (3.99M) | 53.57M | (41.72M) |
| Accounts Receivables | (12.44M) | (8.99M) | 2.25M | (6.72M) | (4.44M) |
| Inventory | 215K | 0 | 0 | 0 | 0 |
| Accounts Payables | 177K | 3.25M | (6.31M) | 2.05M | (3.27M) |
| Other Working Capital | (252K) | 23K | 67K | 58.24M | (34.01M) |
| Other Non-Cash Items | (21.17M) | (7.6M) | 71.95M | (14.61M) | 49.26M |
| Operating Cash Flow | (104.56M) | (87.44M) | (24.75M) | 22.1M | (40.14M) |
| Capital Expenditures | (18.56M) | (2.44M) | (1.07M) | (2.58M) | (2.37M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (143K) | 0 | 0 | (162.48M) | (160.27M) |
| Sales of Investments | 15M | 126K | 0 | 63.69M | 134.24M |
| Other Investing Activities | 10.97M | (456K) | (14.44M) | 0 | 0 |
| Investing Cash Flow | 7.28M | (2.76M) | (15.51M) | (102.63M) | (29.58M) |
| Debt Repayment | (10.64M) | (6.6M) | 24.56M | 18.17M | (5.4M) |
| Common Stock Issued | 44.64M | 0 | 67.94M | 82.68M | 44.14K |
| Common Stock Repurchased | 0 | (569K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 13.53M | 8.32M | (9.64M) | (11.04M) | (10.85M) |
| Financing Cash Flow | 47.53M | 1.15M | 82.87M | 89.8M | (16.2M) |
| Effect of Forex Changes | (5.75M) | (3.36M) | 884K | (2.73M) | 6.24M |
| Net Change in Cash | (55.51M) | (92.42M) | 43.49M | 6.54M | (79.67M) |
| Free Cash Flow | (123.12M) | (89.89M) | (25.82M) | 19.52M | (42.5M) |
Cellectis S.A.
NASDAQ:CLLS
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.